Loading organizations...
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that discovers and develops regulatory RNA-based therapeutics to restore healthy gene expression for genetic diseases. The firm utilizes its Gene Circuitry and RAP platforms to identify druggable targets and upregulate protein production, advancing its lead antisense oligonucleotide candidate, CMP-CPS-001, into Phase 1 clinical trials for urea cycle disorders. Operating with a workforce of 48 to 55 employees, the pre-revenue enterprise relies on external investor capital to fund its research and development pipeline targeting liver and central nervous system disorders. The company transitioned to the public markets through an IPO on October 11, 2024, operating under the leadership of CEO Joshua Mandel-Brehm and board member Amir Nashat. The biotechnology business was originally incorporated in 2015 and officially founded in 2016 by Richard Young and Leonard Zon.
CAMP4 Therapeutics has raised $175.0M across 3 funding rounds.
CAMP4 Therapeutics has raised $175.0M in total across 3 funding rounds.
CAMP4 Therapeutics has raised $175.0M across 3 funding rounds. Most recently, it raised $100.0M Series B in July 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2022 | $100M Series B | James Boylan | 2XN, 5AM Ventures, Aisling Capital, Andreessen Horowitz, Angel Investor, Catalio Capital, Haun Ventures, Highbury Group, Northpond Ventures, OrbiMed, ULU Ventures, What IF Ventures, Wndrco LLC, A16z Scout Fund, Gaingels, Polaris Partners, The Kraft Group | Announced |
| Jun 1, 2021 | $45M Series A | 5AM Ventures, Northpond Ventures | 2XN, Aisling Capital, Andreessen Horowitz, Angel Investor, Catalio Capital, Haun Ventures, Highbury Group, OrbiMed, ULU Ventures, What IF Ventures, Wndrco LLC, A16z Scout Fund, Polaris Partners, The Kraft Group | Announced |
| May 1, 2018 | $30M Series A | Jorge Conde | 2XN, Andreessen Horowitz, Angel Investor, Catalio Capital, Haun Ventures, Highbury Group, ULU Ventures, What IF Ventures, Wndrco LLC, Amir Nashat, The Kraft Group | Announced |
CAMP4 Therapeutics has raised $175.0M in total across 3 funding rounds.
CAMP4 Therapeutics's investors include James Boylan, 2xN, 5AM Ventures, Aisling Capital, Andreessen Horowitz, Angel investor, Catalio Capital, Haun Ventures, Highbury Group, Northpond Ventures, OrbiMed, Ulu Ventures.
# CAMP4 Therapeutics: Pioneering Programmable Gene Therapeutics
CAMP4 Therapeutics is a clinical-stage biopharmaceutical company, not primarily a technology company, though it leverages advanced computational biology and proprietary platforms to develop therapeutics[1][2]. Founded in 2016, CAMP4 develops programmable RNA-based therapeutics (ASOs) designed to upregulate gene expression and restore healthy protein levels across hundreds of diseases[4][5]. The company operates at the intersection of genomics, computational biology, and data sciences, targeting severe and rare genetic disorders where precise gene modulation offers therapeutic promise[2].
The company's core mission is to "realize a world with an effective treatment option for every patient" by modernizing drug discovery through its proprietary Gene Circuitry Platform™[2][3]. Rather than targeting disease symptoms directly, CAMP4 addresses the underlying genetic dysregulation that causes disease, positioning itself as a next-generation approach to genetic medicine that differs from traditional gene therapies and small molecules[1].
CAMP4 was founded in 2016 by Dr. Richard Young (Whitehead Institute/MIT) and Dr. Leonard Zon, whose seminal discoveries characterized how dynamic cell signaling networks control gene expression[2][3]. This scientific foundation—understanding the "control code" for the 24,000 genes in the human body—became the bedrock of CAMP4's innovation[3]. The founders' academic rigor combined with entrepreneurial vision established a company positioned to translate fundamental genomic insights into clinical therapeutics[1].
The company's early momentum centered on building its proprietary 4-D Gene Circuitry Platform, which generates high-resolution maps of how genes are controlled by signaling pathways in specific disease states[2][3]. By 2018, CAMP4 had already generated detailed maps of the liver and its associated disease genes, demonstrating proof-of-concept for the platform's ability to de-risk drug discovery and improve therapeutic predictability[3].
CAMP4 operates within the broader convergence of genomics, artificial intelligence, and precision medicine—trends reshaping drug discovery. The company's timing is advantageous: advances in sequencing, computational power, and our understanding of gene regulation have made programmable therapeutics feasible in ways that were impossible a decade ago[2][3].
The company influences the biotech ecosystem by demonstrating that systematic, data-driven approaches to understanding gene circuitry can accelerate drug development and reduce failure rates. By moving beyond single-target approaches to understanding regulatory networks, CAMP4 exemplifies how computational biology is becoming central to modern drug discovery. This approach has implications for how the entire industry thinks about target identification and validation[3].
CAMP4 stands at an inflection point where foundational science meets clinical application. The company's ability to generate actionable insights from gene circuitry maps positions it to address not just rare genetic disorders but potentially hundreds of diseases by restoring healthy protein levels through programmable therapeutics[2][4].
Looking ahead, CAMP4's trajectory will likely be shaped by: (1) successful clinical validation of its lead programs in neurological and rare disease indications, (2) expansion of its Gene Circuitry Platform across additional human cell types and disease areas, and (3) potential partnerships or licensing deals that leverage its platform's de-risking capabilities[3]. The company's vision to "build the next great biotech company" reflects ambitions to establish programmable gene upregulation as a new therapeutic paradigm—one that could fundamentally alter how the industry approaches genetic disease treatment.
